Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H4E5
UPID:
RHOJ_HUMAN
Alternative names:
Ras-like protein family member 7B; Tc10-like GTP-binding protein
Alternative UPACC:
Q9H4E5; Q96KC1
Background:
Rho-related GTP-binding protein RhoJ, also known as Ras-like protein family member 7B and Tc10-like GTP-binding protein, plays a pivotal role in angiogenesis. This plasma membrane-associated small GTPase is essential for endothelial cell migration during vascular development, facilitated by its interaction with GLUL. RhoJ's function in eliciting the formation of F-actin-rich structures further underscores its critical role in regulating endothelial cell migration.
Therapeutic significance:
Understanding the role of Rho-related GTP-binding protein RhoJ could open doors to potential therapeutic strategies. Its involvement in angiogenesis and endothelial cell migration positions it as a key target for developing treatments aimed at vascular diseases and disorders related to impaired angiogenesis.